Konmik (INN: Flucomabol) is a synthetic antifungal agent from the triazole class. Infections caused by pathogenic fungi represent a significant challenge in intensive care units, as well as in the practice of oncologists, immunologists, and specialists in HIV treatment. Therefore, parenteral antifungal medications are the first line of therapy for severe mycoses.

Konmik has a highly specific action: by inhibiting the activity of cytochrome P450 enzymes in fungal cells, it disrupts the C-14 alpha-demethylation of lanosterol into ergosterol. As a result, the permeability of the cell membrane increases, and the growth and replication of fungal cells are impaired.

Konmik is effective against the most clinically significant fungal pathogens, including Cryptococcus neoformans, Candida spp., dermatophytes, Blastomyces dermatitidis, Coccidioides immitis, Histoplasma capsulatum, and others.

Fluconazole, the active ingredient, has important pharmacokinetic properties, such as good tissue penetration, reaching nearly all tissues and body fluids. In patients with fungal meningitis, the fluconazole concentration in cerebrospinal fluid reaches 80% of the corresponding plasma levels.

With some of the best pharmacodynamic, pharmacokinetic, and safety profiles in its class, Konmik is indicated for empirical therapy of systemic mycoses and generalized fungal infections. It is also the drug of choice for cryptococcal infections of the CNS, lungs, skin, and cryptococcal sepsis, as well as for systemic and generalized candidiasis, histoplasmosis, coccidioidomycosis, sporotrichosis, including in patients with congenital and acquired immunodeficiencies. Additionally, it is used for the prevention of systemic mycoses in at-risk patients.

Based on the indications, initial therapy with Konmik can be continued with oral fluconazole formulations.

View in catalog